Search Results
KRYSTAL-1: adagrasib for KRAS-mutant NSCLC
KRYSTAL-1: activity of adagrasib in KRASG12m NSCLC with untreated CNS metastases
KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer
How will adagrasib fit into the treatment landscape of KRASG12-mutant NSCLC?
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
KRYSTAL-1: next steps in the field of KRASG12C-mutant cancers
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a ...
#ESMO21 Highlights on adagrasib in patients with KRASG12C-mutated CRC: The KRYSTAL-1 study
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC
Adagrasib for Previously Treated KRAS G12C+ NSCLC - ASCO Lung Review 2022
Krystal 7 Study: Adagrasib +/- Pembrolizumab for KRAS G12C+ NSCLC -Targeted Therapies in Lung Cancer
KRYSTAL-1: adagrasib in NSCLC patients with CNS metastases
